There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Titles as Introduced

Protecting Free Trade in Pharmaceuticals Act of 2005

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To clarify that the overall trade negotiating objectives of the United States include avoiding provisions in trade agreements that restrict the access of consumers in the United States to pharmaceutical imports, and for other purposes.


Actions Overview (1)

Date
07/28/2005Introduced in House

All Actions (3)

Date
08/04/2005Referred to the Subcommittee on Trade.
Action By: Committee on Ways and Means
07/28/2005Referred to the House Committee on Ways and Means.
Action By: House of Representatives
07/28/2005Introduced in House
Action By: House of Representatives

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
House Ways and Means07/28/2005 Referred to
House Ways and Means Subcommittee on Trade08/04/2005 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Subjects (16)


Latest Summary (1)

There is one summary for H.R.3583. View summaries

Shown Here:
Introduced in House (07/28/2005)

Protecting Free Trade in Pharmaceuticals Act of 2005 - Amends the Bipartisan Trade Promotion Authority Act of 2002 to include among the overall trade negotiating objectives of the United States avoiding negotiating trade agreements that could restrict, or be interpreted to restrict, the access of consumers in the United States to pharmaceutical imports from countries with a pharmaceutical infrastructure that is equivalent, or superior, to that of the United States: (1) by or through the use and development of the doctrine of international patent exhaustion, as interpreted or applied by U.S. courts on the enactment of this Act; or (2) by making it a violation for the United States to enact legislation permitting pharmaceutical imports without the consent of patent owners when the products involved have been sold outside the United States.

Prohibits the U.S. Trade Representative (USTR) from: (1) entering into a bilateral or multilateral trade agreement that, with respect to the importation of pharmaceutical products without the consent of the patent owners, includes provisions identical or similar to the provisions of the United States-Singapore Free Trade Agreement, the United States-Australia Free Trade Agreement, or the United States-Morocco Free Trade Agreement; or (2) negotiating an agreement or understanding with respect to any of such provisions.

Requires the USTR, with respect to the advisory committee on matters relating to intellectual property, to ensure that, for each meeting that relates or potentially relates to the importation of pharmaceutical products into the United States, at least 10% of the committee members represent the interests of consumers of such products.